Alector Stock Forecast, Price & News

Alector's stock was trading at $24.92 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ALEC shares have decreased by 60.6% and is now trading at $9.81.
View which stocks have been most impacted by COVID-19.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Alector.

Alector is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Alector.

Alector, Inc. (NASDAQ:ALEC) issued its earnings results on Tuesday, August, 11th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by $0.09. The firm had revenue of $3.17 million for the quarter, compared to analyst estimates of $8.84 million. Alector had a negative net margin of 775.34% and a negative return on equity of 50.88%.
View Alector's earnings history.

8 Wall Street analysts have issued 1-year price targets for Alector's stock. Their forecasts range from $28.00 to $41.00. On average, they expect Alector's stock price to reach $32.80 in the next twelve months. This suggests a possible upside of 234.4% from the stock's current price.
View analysts' price targets for Alector.

Alector saw a increase in short interest during the month of September. As of September 30th, there was short interest totaling 10,670,000 shares, an increase of 26.6% from the September 15th total of 8,430,000 shares. Based on an average trading volume of 1,020,000 shares, the days-to-cover ratio is presently 10.5 days. Currently, 19.1% of the company's shares are sold short.
View Alector's Short Interest.

Some companies that are related to Alector include SpringWorks Therapeutics (SWTX), Revolution Medicines (RVMD), Vaxcyte (PCVX), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Beam Therapeutics (BEAM), Forma Therapeutics (FMTX), Bavarian Nordic A/S (BVNRY), Replimune Group (REPL), AlloVir (ALVR), Sangamo Therapeutics (SGMO), Kymera Therapeutics (KYMR), Cortexyme (CRTX), NanoString Technologies (NSTG) and Mesoblast (MESO).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Pfizer (PFE), Advanced Micro Devices (AMD), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), QUALCOMM (QCOM), Intel (INTC), Micron Technology (MU) and Cisco Systems (CSCO).

(ALEC) raised $177 million in an initial public offering (IPO) on Thursday, February 7th 2019. The company issued 9,300,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays acted as the underwriters for the IPO.

Alector trades on the NASDAQ under the ticker symbol "ALEC."

Alector's stock is owned by a variety of retail and institutional investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.20%), Exane Derivatives (0.01%) and Exane Derivatives (0.01%). Company insiders that own Alector stock include Calvin Yu, David M Wehner, Orbimed Advisors Llc, Robert King, Robert Paul, Sabah Oney and Terrance Mcguire.
View institutional ownership trends for Alector.

ALEC stock was acquired by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Exane Derivatives, and Exane Derivatives. Company insiders that have bought Alector stock in the last two years include David M Wehner, and Orbimed Advisors Llc.
View insider buying and selling activity for Alector.

Shares of ALEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALEC stock can currently be purchased for approximately $9.81.

Alector has a market capitalization of $777.54 million and generates $21.22 million in revenue each year. The company earns $-105,390,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis. Alector employs 153 workers across the globe.

The official website for Alector is www.alector.com.

Alector's mailing address is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-231-5660 or via email at [email protected]